查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1856475

何杰金氏淋巴瘤（HL）治疗市场按治疗类型、分期、治疗线数、分子类型和患者年龄划分－全球预测，2025-2032年

Hodgkin Lymphoma Treatment Market by Treatment Type, Disease Stage, Treatment Line, Molecule Type, Patient Age - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，何杰金氏淋巴瘤(HL) 治疗市场将成长至 27.1 亿美元，复合年增长率为 9.51%。

关键市场统计数据
基准年 2024 13.1亿美元
预计年份：2025年 14.3亿美元
预测年份 2032 27.1亿美元
复合年增长率 (%) 9.51%

一份简洁且全面的框架，阐述了不断发展的何杰金氏淋巴瘤（HL）治疗格局如何影响临床、监管和商业性决策。

何杰金氏淋巴瘤(HL) 的治疗已进入一个以治疗创新、临床实践发展和监管预期变化为特征的新时代。儘管化疗和放射线治疗等传统治疗方法仍然是多模式治疗的重要组成部分，但免疫疗法和标靶药物的最新进展正在再形成临床决策路径。同时，对患者族群特征和存活期的关注也推动着治疗方法选择和长期毒性管理的改进。

免疫疗法、精准放射线治疗和生物标记主导的临床设计方面的突破性进展如何从根本上改变何杰金氏淋巴瘤(HL) 的治疗路径和相关人员的优先事项

何杰金氏淋巴瘤的治疗格局正在经历一场变革，这主要得益于科学突破、治疗模式的演变以及以患者为中心的护理理念。针对免疫查核点的免疫疗法药物和抗体药物复合体正在重新定义预期疗效，并为过去仅接受细胞毒性药物治疗的患者开闢新的治疗选择。同时，放射治疗技术的进步，包括自我调整计画和质子束放射治疗，与全身性治疗相结合，正在降低继发性毒性，并实现更精准的局部控制。

了解2025年美国贸易政策调整对何杰金氏淋巴瘤（HL）治疗交付和产业策略的营运、供应链和进入影响。

美国将于2025年实施新的关税政策，将对何杰金氏淋巴瘤（HL）治疗生态系统产生多方面的影响，涉及商业物流、供应链韧性和准入等诸多方面。关税调整可能会改变进口活性药物原料药以及放射治疗和药物生产中使用的专用设备的成本结构，迫使製造商重新评估筹资策略和供应商合约。这些营运方面的变化往往会引发一系列策略选择，例如将供应链的部分环节迁回国内、实现供应商多元化以及谈判长期采购协议以降低贸易政策波动带来的风险。

基于深度细分的洞察，将治疗方式、分期、分子分型、治疗线数和患者年龄层与可操作的临床和商业性意义联繫起来。

深入的细分揭示了不同治疗方式、疾病阶段、治疗线数、分子分型和患者年龄层之间截然不同的临床和商业动态。依治疗类型分析，可选择的治疗方案包括ABVD、BEACOPP等化疗方案和脂质体製剂、免疫疗法、放射线治疗（包括自我调整计划、受累野技术和质子疗法）以及分子标靶疗法。每种治疗方法都有独特的疗效和毒性特征，可为患者选择和治疗顺序提供依据。

美洲、欧洲、中东和非洲以及亚太地区的临床、监管和准入动态将影响区域策略和病患准入途径。

区域动态影响美洲、欧洲、中东和非洲以及亚太地区的临床实践模式、监管时间表和准入策略。在美洲，整合的肿瘤学网络和已建立的临床路径促进了循证方案的快速应用，而报销机制和与支付方的谈判则决定了高成本生物製药和先进放射治疗技术的可及性。跨境合作和学术中心在临床试验註册和转化研究中也发挥着重要作用。

临床产品组合、策略伙伴关係、供应链能力和实证医学成果等因素塑造的竞争动态，将决定何杰金氏淋巴瘤（HL）治疗领域的长期差异化优势。

竞争格局呈现出多元化的特点，既有成熟的肿瘤治疗公司，也有专注于抗体和小分子疗法的生物技术公司，以及专注于放射肿瘤硬体和软体的技术合作伙伴。主要企业凭藉其临床产品组合、生物标记主导的研发能力、策略联盟以及在监管和支付方环境中的经验脱颖而出。除了产品平臺之外，各公司还透过投资生物製药生产能力、全球供应链网络以及真实世界证据的产生来支撑其长期价值提案，从而实现差异化竞争。

为製造商和医疗服务提供者提供营运和策略建议，以协调临床开发、供应链韧性和支付方参与，从而改善患者疗效。

行业领导者应采取整合策略，协调临床开发、商业策略和市场准入计划，确保治疗方案惠及最需要的患者。首先，应优先进行以生物标记主导的队列研究和患者报告结局为指标的临床项目，以证明治疗效果超越了传统的疗效指标。这种策略将有助于加强监管和医疗保险报销方面的讨论，并支持重视持久缓解和生活品质的临床医生采纳相关治疗方案。

采用严谨的多源调查方法，结合文献综述、专家访谈和跨细分市场分析，得出可操作的临床和商业性见解。

本调查方法采用多源方法，结合了系统性文献综述、专家访谈以及对监管和临床实践文件的定性分析。第一手资料包括同行评审的临床研究、共识指南以及主要肿瘤学会的意见，这些文献经过综合分析，反映了目前的临床实践和治疗原理。次要文献来源包括临床试验註册资讯、监管核准以及已发表的真实世界研究，这些研究为研究方法的应用和结果比较提供了背景资讯。

整合临床创新、业务需求和策略重点，以明确何杰金氏淋巴瘤(HL) 治疗和医疗服务取得的未来方向。

总之，何杰金氏淋巴瘤(HL) 的治疗格局呈现出显着的临床创新、不断发展的治疗标准以及复杂的运作考量等特点，这些因素共同影响着患者的治疗机会和治疗策略。新型免疫疗法和标靶分子正在重塑临床治疗手段，而放射疗法的进步则在降低毒性的同时，拓展了局部疾病控制的选择。为了优化不同族群的治疗效果，必须综合考虑疾病分期、治疗线数、分子分型和患者年龄等因素，全面评估这些临床进展。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 将PD-1查核点抑制剂整合到难治性何杰金氏淋巴瘤患者的第一线治疗通讯协定中
  • 在復发或难治性何杰金氏淋巴瘤患者中诱导CD30靶向CAR-T细胞疗法
  • 循环肿瘤DNA检测在监测何杰金氏淋巴瘤（HL）微量残存疾病和指南治疗的新兴作用
  • 生物相似药布伦妥昔单抗（brentuximab vedotin）上市对晚期何杰金氏淋巴瘤治疗定价与可近性的影响
  • 扩大真实世界证据研究在评估何杰金氏淋巴瘤（HL）倖存者长期安全性结果的应用
  • 开发靶向 PD-1 和 CD30 的双特异性抗体以增强何杰金氏淋巴瘤(HL) 的免疫疗法疗效
  • 在復发性何杰金氏淋巴瘤患者中扩大查核点抑制剂和挽救化疗的组合方案

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章何杰金氏淋巴瘤（HL）治疗市场（按治疗类型划分）

  • 化疗
    • ABVD疗法
    • 贝科普疗法
    • 脂质体配方
  • 免疫疗法
  • 放射线治疗
    • 自我调整放射线治疗
    • 受累野放射线治疗
    • 质子治疗
  • 标靶治疗

第九章何杰金氏淋巴瘤（HL）治疗市场依疾病分期划分

  • 晚期
    • 第三阶段
    • 第四阶段
  • 早期的
    • 第一阶段
    • 第二阶段

第十章何杰金氏淋巴瘤（HL）治疗市场（依治疗线划分）

  • 首选药物
  • 二线药物
  • 三线药物

第十一章何杰金氏淋巴瘤（HL）治疗市场（按分子类型划分）

  • 单株抗体
    • CD30标靶抗体
      • 维布妥昔单抗
      • 新一代抗体
    • PD-1抑制剂
      • Nivolumab
      • Pembrolizumab
  • 低分子化合物
    • 组蛋白去乙酰化酶抑制剂
      • 下一代 HDAC 抑制剂
      • 罗米地辛
      • 沃里诺斯塔特

第十二章何杰金氏淋巴瘤（HL）治疗市场（依病患年龄划分）

  • 成人
  • 老年人
  • 儿童

第十三章何杰金氏淋巴瘤（HL）治疗市场（按地区划分）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章何杰金氏淋巴瘤（HL）治疗市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 各国何杰金氏淋巴瘤（HL）治疗市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Takeda Pharmaceutical Company Limited
    • Bristol-Myers Squibb Company
    • Merck & Co., Inc.
    • Gilead Sciences, Inc.
    • Novartis AG
    • Roche Holding AG
    • Johnson & Johnson
    • Pfizer Inc.
    • Seagen Inc.
    • Kite Pharma, Inc.
Product Code: MRR-742BD517F76D

The Hodgkin Lymphoma Treatment Market is projected to grow by USD 2.71 billion at a CAGR of 9.51% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 1.31 billion
Estimated Year [2025] USD 1.43 billion
Forecast Year [2032] USD 2.71 billion
CAGR (%) 9.51%

A concise yet comprehensive framing of the evolving Hodgkin lymphoma treatment environment that shapes clinical, regulatory, and commercial decision-making

Hodgkin lymphoma treatment has entered an era marked by converging therapeutic innovation, evolving clinical practice, and shifting regulatory expectations. Recent advances in immunotherapy and targeted agents are reshaping clinical decision pathways while established modalities such as chemotherapy and radiotherapy remain integral to multidisciplinary care. At the same time, patient demographics and survivorship concerns are driving refinements in treatment selection and long-term toxicity management.

This introduction frames the landscape by outlining the interplay between novel agents and legacy treatments that together define contemporary therapeutic choices. It also highlights the importance of integrating disease staging and line of therapy considerations into clinical strategies, as these parameters influence eligibility for specific modalities and sequencing decisions. Moreover, greater emphasis on molecular characterization and biomarker-driven approaches is enabling more precise patient stratification, which in turn affects clinical trial design and real-world prescribing.

As stakeholders navigate this complex environment, they must balance efficacy, safety, and quality-of-life outcomes across adult, geriatric, and pediatric populations. In the following sections, the report examines transformative shifts, regulatory and policy influences including tariff dynamics, segmentation insights, and regional and competitive landscapes to provide a cohesive foundation for strategic decision-making and operational planning.

How breakthroughs in immunotherapy, precision radiotherapy, and biomarker-driven clinical designs are fundamentally reshaping Hodgkin lymphoma care pathways and stakeholder priorities

The Hodgkin lymphoma landscape is undergoing transformative shifts driven by scientific breakthroughs, evolving therapeutic paradigms, and patient-centered care priorities. Immunotherapy agents that engage the immune checkpoint and antibody-drug conjugate modalities are redefining response expectations and creating new options for patients who were historically treated with cytotoxic regimens alone. Concurrently, advances in radiotherapy, including adaptive planning and proton delivery, are reducing collateral toxicity and enabling more precise local control when combined with systemic therapies.

Translational science is accelerating the identification of biomarkers that inform patient selection and optimize therapeutic sequencing. As a result, clinical trial designs are progressively more adaptive, incorporating biomarker-enriched cohorts and novel endpoints that reflect durable responses and long-term survivorship. This shift toward personalized regimens is complemented by improvements in supportive care, which mitigate acute and late adverse events and facilitate outpatient treatment delivery.

Operationally, stakeholders must respond to changing reimbursement frameworks and payer expectations that increasingly value real-world evidence and long-term outcomes. In practice, multidisciplinary collaboration among hematologists, radiation oncologists, and allied specialists is becoming the cornerstone of care pathways. Consequently, organizations that align product development, clinical programs, and commercial strategies with these transformative trends will be positioned to deliver meaningful value to patients and providers.

Understanding the operational, supply chain, and access implications of U.S. trade policy adjustments in 2025 for Hodgkin lymphoma treatment delivery and industrial strategy

The introduction of new tariff policies in the United States for 2025 presents multifaceted implications for the Hodgkin lymphoma treatment ecosystem, touching commercial logistics, supply chain resilience, and access considerations. Tariff adjustments can alter the cost structure for imported active pharmaceutical ingredients and specialized equipment used in radiotherapy and drug manufacturing, which may prompt manufacturers to revisit sourcing strategies and supplier contracts. These operational shifts often cascade into strategic choices about onshoring components of the supply chain, diversifying supplier bases, and negotiating long-term procurement agreements to mitigate exposure to trade policy volatility.

In addition, tariffs can influence the competitiveness of certain therapeutic modalities by affecting the relative cost of advanced radiotherapy technologies and complex biologic therapies that rely on imported components. For healthcare providers and integrated delivery networks, policy-driven cost pressures may accelerate value-based contracting and require closer collaboration with manufacturers to articulate clinical and economic value. As a result, payors and hospital systems could increase scrutiny on comparative effectiveness and total cost of care when evaluating formulary placement or capital investments.

Finally, the policy environment underscores the importance of proactive regulatory and market access planning. Manufacturers should model tariff scenarios in commercial operations planning, engage with trade and policy experts, and develop contingency strategies that preserve supply continuity and patient access. In parallel, clinical leaders and advocacy groups will need to communicate the clinical necessity of sustaining access to specialized therapies and technologies to minimize unintended disruptions to care delivery.

Deep segmentation-driven insights linking therapeutic modalities, disease staging, molecule classes, treatment lines, and patient age cohorts to practical clinical and commercial implications

Insightful segmentation illuminates distinct clinical and commercial dynamics across treatment modalities, disease stages, therapy lines, molecule classes, and patient age cohorts. When analyzed by treatment type, the landscape encompasses chemotherapy regimens such as ABVD, BEACOPP, and liposomal formulations alongside immunotherapy, radiotherapy approaches that include adaptive planning, involved-field techniques, and proton therapy, and targeted therapies that provide molecularly directed options. Each modality presents unique efficacy and toxicity profiles that inform patient selection and sequencing.

Considering disease stage, early-stage patients categorized into Stage I and Stage II typically follow different therapeutic pathways and survivorship priorities compared with advanced-stage patients in Stage III and Stage IV, where systemic control and durable remission are central objectives. Treatment line segmentation further differentiates clinical strategy, with first-line approaches emphasizing curative intent and second-line and third-line interventions focusing on salvage, bridging to transplant, or palliative control as appropriate.

From a molecule perspective, monoclonal antibodies, including CD30-directed agents such as brentuximab vedotin and next-generation antibodies as well as PD-1 inhibitors represented by agents like nivolumab and pembrolizumab, offer immune-mediated mechanisms that complement or replace cytotoxic therapy in some settings. Small molecules, notably histone deacetylase inhibitors including romidepsin, vorinostat, and next-generation HDAC candidates, provide epigenetic modulation options in select indications. Finally, patient age stratification into adult, geriatric, and pediatric groups influences dosing, treatment tolerance, and long-term monitoring, shaping both clinical trial design and real-world management pathways.

Regional clinical, regulatory, and access dynamics across the Americas, Europe Middle East & Africa, and Asia-Pacific that shape localized strategy and patient access pathways

Regional dynamics influence clinical practice patterns, regulatory timelines, and access strategies across the Americas, Europe Middle East & Africa, and Asia-Pacific. In the Americas, integrated oncology networks and established clinical pathways facilitate rapid adoption of evidence-based protocols, while reimbursement mechanisms and payer negotiations shape access to high-cost biologics and advanced radiotherapy technologies. Cross-border collaboration and academic centers also play a prominent role in clinical trial enrollment and translational research.

Across Europe, the Middle East and Africa, heterogeneous regulatory frameworks and variable healthcare infrastructure lead to a mosaic of treatment availability and uptake. In many markets, centralized evaluation bodies and health technology assessment processes require robust clinical and economic evidence to support coverage decisions, which impacts launch sequencing and local evidence-generation strategies. Collaboration with regional clinical leaders and patient advocacy organizations is essential to navigate these environments and to align value demonstration with local priorities.

In the Asia-Pacific region, diverse healthcare delivery models coexist with rapidly expanding clinical research capacity and growing emphasis on domestic manufacturing and supply security. Policymakers and providers in this region are increasingly focused on cost-effective adoption of innovative therapies, and strategic partnerships with regional stakeholders can accelerate access while addressing logistical and regulatory challenges. Across all regions, a nuanced understanding of local clinical guidelines, reimbursement landscapes, and infrastructure constraints is crucial for tailoring market entry and access strategies.

Competitive dynamics shaped by clinical portfolios, strategic partnerships, supply chain capabilities, and evidence generation that determine long-term differentiation in Hodgkin lymphoma care

The competitive landscape is characterized by a mix of established oncology players, specialist biotech firms advancing antibody and small-molecule programs, and technology partners focused on radiotherapy hardware and software. Leading organizations are differentiated by their clinical portfolios, capabilities in biomarker-driven development, strategic collaborations, and experience navigating regulatory and payer environments. In addition to product pipelines, companies distinguish themselves through manufacturing capacity for biologics, global supply chain networks, and investments in real-world evidence generation to support long-term value propositions.

Strategic partnerships between pharmaceutical developers and radiation technology providers are increasingly common as multidisciplinary treatment approaches require coordination between systemic therapies and precision radiotherapy. Moreover, companies that invest in patient support programs, digital health tools for treatment monitoring, and clinician education initiatives are better positioned to demonstrate real-world benefits and foster uptake. Intellectual property portfolios, licensing arrangements for next-generation molecules, and early-stage clinical data will also influence competitive positioning as novel agents advance through development.

Ultimately, successful companies combine robust clinical strategies with agile commercial execution, proactive engagement with payers and regulators, and a commitment to evidence generation that captures both clinical outcomes and survivorship metrics. These capabilities enable sustained differentiation in a complex, evolving therapeutic environment.

Operational and strategic recommendations for manufacturers and providers to align clinical development, supply chain resilience, and payer engagement for improved patient outcomes

Industry leaders should pursue an integrated approach that aligns clinical development, commercial strategy, and access planning to ensure therapies reach the patients who will benefit most. First, prioritize clinical programs that incorporate biomarker-driven cohorts and patient-reported outcomes to demonstrate meaningful benefit beyond traditional response metrics. This approach strengthens regulatory and reimbursement conversations and supports adoption by clinicians focused on durable remissions and quality of life.

Second, invest in supply chain resilience by diversifying sourcing and engaging in scenario planning for trade and policy contingencies. Manufacturers should assess the implications of tariffs and logistical constraints and consider regional manufacturing or strategic stockpiles to minimize disruption. Third, foster multidisciplinary collaborations that bring together systemic therapy experts, radiation oncology teams, and supportive care specialists to optimize combination approaches and sequencing in clinical practice.

Fourth, engage early with payers, health technology assessment bodies, and clinician networks to co-develop evidence generation plans that reflect local decision criteria. Fifth, leverage digital tools and patient support programs to improve adherence, monitor adverse events, and capture real-world effectiveness. By executing on these recommendations, organizations can accelerate clinical impact, reinforce value propositions, and improve patient outcomes across diverse care settings.

A rigorous multi-source research methodology combining literature synthesis, expert interviews, and cross-segmentation analysis to derive actionable clinical and commercial insights

This research integrates a multi-source methodology combining systematic literature synthesis, expert interviews, and qualitative analysis of regulatory and clinical practice documents. Primary inputs include peer-reviewed clinical studies, consensus guidelines, and position statements from major oncology societies, which have been synthesized to reflect contemporary clinical practice and therapeutic rationale. Secondary materials encompass clinical trial registries, regulatory approvals, and published real-world studies that provide context for adoption and comparative outcomes.

Additionally, the study incorporates structured interviews with clinicians, clinical trial investigators, and commercial leaders to capture frontline perspectives on treatment selection, sequencing, and access barriers. These expert insights supplement the evidence base and help interpret variability across disease stages, treatment lines, and regional practices. Analytical techniques include cross-segmentation mapping to identify clinical and commercial intersections, scenario analysis for policy impacts, and qualitative synthesis to derive actionable recommendations.

Throughout, methodological rigor was maintained by triangulating findings across multiple sources and transparently documenting assumptions and evidence gaps. Limitations of the analysis are acknowledged where published data are incomplete, and areas recommended for further primary research are identified to support ongoing strategic decision-making.

Synthesis of clinical innovation, operational imperatives, and strategic priorities that collectively define the future direction of Hodgkin lymphoma treatment and access

In conclusion, the Hodgkin lymphoma treatment landscape is characterized by meaningful clinical innovation, evolving standards of care, and complex operational considerations that jointly influence access and therapeutic strategy. Novel immunotherapies and targeted molecules are reshaping the clinical toolkit while advances in radiotherapy delivery expand options for localized disease control with reduced toxicity. These clinical advances must be considered in the context of disease stage, treatment line, molecule class, and patient age to optimize outcomes across diverse populations.

Operational and policy shifts, including tariff changes and regional reimbursement dynamics, underscore the need for proactive planning across manufacturing, supply chain, and payer engagement. Companies and clinical leaders that prioritize evidence generation, multidisciplinary collaboration, and resilient commercialization strategies will be best positioned to translate therapeutic innovation into improved patient care. Finally, ongoing data collection-both in controlled trials and real-world settings-will remain essential to refine practice, support coverage decisions, and ensure sustained access to effective treatments.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of PD-1 checkpoint inhibitors into frontline therapy protocols for refractory Hodgkin lymphoma patients
  • 5.2. Adoption of CD30-directed CAR T-cell therapies in relapsed or refractory Hodgkin lymphoma treatment landscapes
  • 5.3. Emerging role of circulating tumor DNA assays to monitor minimal residual disease and guide Hodgkin lymphoma therapy
  • 5.4. Impact of biosimilar brentuximab vedotin entries on pricing dynamics and access to advanced Hodgkin lymphoma therapies
  • 5.5. Increasing utilization of real-world evidence studies to assess long-term safety outcomes in Hodgkin lymphoma survivors
  • 5.6. Development of bispecific antibodies targeting PD-1 and CD30 to enhance immunotherapeutic efficacy in Hodgkin lymphoma
  • 5.7. Expansion of combination regimens merging checkpoint inhibitors with salvage chemotherapy in relapsed Hodgkin lymphoma patients

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Hodgkin Lymphoma Treatment Market, by Treatment Type

  • 8.1. Chemotherapy
    • 8.1.1. Abvd Regimen
    • 8.1.2. Beacopp Regimen
    • 8.1.3. Liposomal Formulations
  • 8.2. Immunotherapy
  • 8.3. Radiotherapy
    • 8.3.1. Adaptive Radiotherapy
    • 8.3.2. Involved-Field Radiotherapy
    • 8.3.3. Proton Radiotherapy
  • 8.4. Targeted Therapy

9. Hodgkin Lymphoma Treatment Market, by Disease Stage

  • 9.1. Advanced Stage
    • 9.1.1. Stage III
    • 9.1.2. Stage IV
  • 9.2. Early Stage
    • 9.2.1. Stage I
    • 9.2.2. Stage II

10. Hodgkin Lymphoma Treatment Market, by Treatment Line

  • 10.1. First Line
  • 10.2. Second Line
  • 10.3. Third Line

11. Hodgkin Lymphoma Treatment Market, by Molecule Type

  • 11.1. Monoclonal Antibodies
    • 11.1.1. Cd30 Directed Antibodies
      • 11.1.1.1. Brentuximab Vedotin
      • 11.1.1.2. Next Generation Antibodies
    • 11.1.2. Pd-1 Inhibitors
      • 11.1.2.1. Nivolumab
      • 11.1.2.2. Pembrolizumab
  • 11.2. Small Molecules
    • 11.2.1. Histone Deacetylase Inhibitors
      • 11.2.1.1. Next Generation Hdac Inhibitors
      • 11.2.1.2. Romidepsin
      • 11.2.1.3. Vorinostat

12. Hodgkin Lymphoma Treatment Market, by Patient Age

  • 12.1. Adult
  • 12.2. Geriatric
  • 12.3. Pediatric

13. Hodgkin Lymphoma Treatment Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Hodgkin Lymphoma Treatment Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Hodgkin Lymphoma Treatment Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Takeda Pharmaceutical Company Limited
    • 16.3.2. Bristol-Myers Squibb Company
    • 16.3.3. Merck & Co., Inc.
    • 16.3.4. Gilead Sciences, Inc.
    • 16.3.5. Novartis AG
    • 16.3.6. Roche Holding AG
    • 16.3.7. Johnson & Johnson
    • 16.3.8. Pfizer Inc.
    • 16.3.9. Seagen Inc.
    • 16.3.10. Kite Pharma, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY DISEASE STAGE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY DISEASE STAGE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT LINE, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT LINE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY MOLECULE TYPE, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY MOLECULE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PATIENT AGE, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PATIENT AGE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. HODGKIN LYMPHOMA TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. HODGKIN LYMPHOMA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. HODGKIN LYMPHOMA TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ABVD REGIMEN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ABVD REGIMEN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ABVD REGIMEN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ABVD REGIMEN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ABVD REGIMEN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ABVD REGIMEN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY BEACOPP REGIMEN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY BEACOPP REGIMEN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY BEACOPP REGIMEN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY BEACOPP REGIMEN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY BEACOPP REGIMEN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY BEACOPP REGIMEN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY LIPOSOMAL FORMULATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY LIPOSOMAL FORMULATIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY LIPOSOMAL FORMULATIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY LIPOSOMAL FORMULATIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY LIPOSOMAL FORMULATIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY LIPOSOMAL FORMULATIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY RADIOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY RADIOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY RADIOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY RADIOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY RADIOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY RADIOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ADAPTIVE RADIOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ADAPTIVE RADIOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ADAPTIVE RADIOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ADAPTIVE RADIOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ADAPTIVE RADIOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ADAPTIVE RADIOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY INVOLVED-FIELD RADIOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY INVOLVED-FIELD RADIOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY INVOLVED-FIELD RADIOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY INVOLVED-FIELD RADIOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY INVOLVED-FIELD RADIOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY INVOLVED-FIELD RADIOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PROTON RADIOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PROTON RADIOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PROTON RADIOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PROTON RADIOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PROTON RADIOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PROTON RADIOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY DISEASE STAGE, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY DISEASE STAGE, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ADVANCED STAGE, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ADVANCED STAGE, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ADVANCED STAGE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ADVANCED STAGE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ADVANCED STAGE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ADVANCED STAGE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ADVANCED STAGE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ADVANCED STAGE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY STAGE III, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY STAGE III, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY STAGE III, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY STAGE III, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY STAGE III, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY STAGE III, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY STAGE IV, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY STAGE IV, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY STAGE IV, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY STAGE IV, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY STAGE IV, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY STAGE IV, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY EARLY STAGE, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY EARLY STAGE, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY EARLY STAGE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY EARLY STAGE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY EARLY STAGE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY EARLY STAGE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY EARLY STAGE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY EARLY STAGE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY STAGE I, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY STAGE I, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY STAGE I, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY STAGE I, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY STAGE I, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY STAGE I, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY STAGE II, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY STAGE II, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY STAGE II, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY STAGE II, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY STAGE II, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY STAGE II, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT LINE, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY FIRST LINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY FIRST LINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY FIRST LINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY FIRST LINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY FIRST LINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY SECOND LINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY SECOND LINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY SECOND LINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY SECOND LINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY SECOND LINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY THIRD LINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY THIRD LINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY THIRD LINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY THIRD LINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY THIRD LINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY THIRD LINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY MOLECULE TYPE, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CD30 DIRECTED ANTIBODIES, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CD30 DIRECTED ANTIBODIES, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CD30 DIRECTED ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CD30 DIRECTED ANTIBODIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CD30 DIRECTED ANTIBODIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CD30 DIRECTED ANTIBODIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CD30 DIRECTED ANTIBODIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CD30 DIRECTED ANTIBODIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY BRENTUXIMAB VEDOTIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY BRENTUXIMAB VEDOTIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY BRENTUXIMAB VEDOTIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY BRENTUXIMAB VEDOTIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY BRENTUXIMAB VEDOTIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY BRENTUXIMAB VEDOTIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY NEXT GENERATION ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY NEXT GENERATION ANTIBODIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY NEXT GENERATION ANTIBODIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY NEXT GENERATION ANTIBODIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY NEXT GENERATION ANTIBODIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY NEXT GENERATION ANTIBODIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PD-1 INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PD-1 INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PD-1 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PD-1 INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PD-1 INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PD-1 INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PD-1 INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PD-1 INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY NIVOLUMAB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY NIVOLUMAB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY NIVOLUMAB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY NIVOLUMAB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY NIVOLUMAB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY NIVOLUMAB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PEMBROLIZUMAB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PEMBROLIZUMAB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PEMBROLIZUMAB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PEMBROLIZUMAB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PEMBROLIZUMAB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PEMBROLIZUMAB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY SMALL MOLECULES, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY SMALL MOLECULES, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY SMALL MOLECULES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY SMALL MOLECULES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY SMALL MOLECULES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY SMALL MOLECULES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY SMALL MOLECULES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY SMALL MOLECULES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY HISTONE DEACETYLASE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY HISTONE DEACETYLASE INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY HISTONE DEACETYLASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY HISTONE DEACETYLASE INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY HISTONE DEACETYLASE INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY HISTONE DEACETYLASE INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY HISTONE DEACETYLASE INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY HISTONE DEACETYLASE INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY NEXT GENERATION HDAC INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY NEXT GENERATION HDAC INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY NEXT GENERATION HDAC INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY NEXT GENERATION HDAC INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY NEXT GENERATION HDAC INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY NEXT GENERATION HDAC INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ROMIDEPSIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ROMIDEPSIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ROMIDEPSIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ROMIDEPSIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ROMIDEPSIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ROMIDEPSIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY VORINOSTAT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY VORINOSTAT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY VORINOSTAT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY VORINOSTAT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY VORINOSTAT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY VORINOSTAT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PATIENT AGE, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PATIENT AGE, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ADULT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ADULT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ADULT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ADULT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ADULT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY GERIATRIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY GERIATRIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PEDIATRIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PEDIATRIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 239. AMERICAS HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 240. AMERICAS HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 241. AMERICAS HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 242. AMERICAS HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 243. AMERICAS HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 244. AMERICAS HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 245. AMERICAS HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 246. AMERICAS HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 247. AMERICAS HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY DISEASE STAGE, 2018-2024 (USD MILLION)
  • TABLE 248. AMERICAS HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY DISEASE STAGE, 2025-2032 (USD MILLION)
  • TABLE 249. AMERICAS HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ADVANCED STAGE, 2018-2024 (USD MILLION)
  • TABLE 250. AMERICAS HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ADVANCED STAGE, 2025-2032 (USD MILLION)
  • TABLE 251. AMERICAS HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY EARLY STAGE, 2018-2024 (USD MILLION)
  • TABLE 252. AMERICAS HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY EARLY STAGE, 2025-2032 (USD MILLION)
  • TABLE 253. AMERICAS HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
  • TABLE 254. AMERICAS HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT LINE, 2025-2032 (USD MILLION)
  • TABLE 255. AMERICAS HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
  • TABLE 256. AMERICAS HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY MOLECULE TYPE, 2025-2032 (USD MILLION)
  • TABLE 257. AMERICAS HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
  • TABLE 258. AMERICAS HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2032 (USD MILLION)
  • TABLE 259. AMERICAS HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CD30 DIRECTED ANTIBODIES, 2018-2024 (USD MILLION)
  • TABLE 260. AMERICAS HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CD30 DIRECTED ANTIBODIES, 2025-2032 (USD MILLION)
  • TABLE 261. AMERICAS HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PD-1 INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 262. AMERICAS HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PD-1 INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 263. AMERICAS HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY SMALL MOLECULES, 2018-2024 (USD MILLION)
  • TABLE 264. AMERICAS HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY SMALL MOLECULES, 2025-2032 (USD MILLION)
  • TABLE 265. AMERICAS HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY HISTONE DEACETYLASE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 266. AMERICAS HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY HISTONE DEACETYLASE INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 267. AMERICAS HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PATIENT AGE, 2018-2024 (USD MILLION)
  • TABLE 268. AMERICAS HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PATIENT AGE, 2025-2032 (USD MILLION)
  • TABLE 269. NORTH AMERICA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 270. NORTH AMERICA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 271. NORTH AMERICA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 272. NORTH AMERICA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 273. NORTH AMERICA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 274. NORTH AMERICA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 275. NORTH AMERICA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 276. NORTH AMERICA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 277. NORTH AMERICA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY DISEASE STAGE, 2018-2024 (USD MILLION)
  • TABLE 278. NORTH AMERICA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY DISEASE STAGE, 2025-2032 (USD MILLION)
  • TABLE 279. NORTH AMERICA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ADVANCED STAGE, 2018-2024 (USD MILLION)
  • TABLE 280. NORTH AMERICA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ADVANCED STAGE, 2025-2032 (USD MILLION)
  • TABLE 281. NORTH AMERICA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY EARLY STAGE, 2018-2024 (USD MILLION)
  • TABLE 282. NORTH AMERICA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY EARLY STAGE, 2025-2032 (USD MILLION)
  • TABLE 283. NORTH AMERICA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
  • TABLE 284. NORTH AMERICA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT LINE, 2025-2032 (USD MILLION)
  • TABLE 285. NORTH AMERICA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
  • TABLE 286. NORTH AMERICA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY MOLECULE TYPE, 2025-2032 (USD MILLION)
  • TABLE 287. NORTH AMERICA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
  • TABLE 288. NORTH AMERICA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2032 (USD MILLION)
  • TABLE 289. NORTH AMERICA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CD30 DIRECTED ANTIBODIES, 2018-2024 (USD MILLION)
  • TABLE 290. NORTH AMERICA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CD30 DIRECTED ANTIBODIES, 2025-2032 (USD MILLION)
  • TABLE 291. NORTH AMERICA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PD-1 INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 292. NORTH AMERICA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PD-1 INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 293. NORTH AMERICA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY SMALL MOLECULES, 2018-2024 (USD MILLION)
  • TABLE 294. NORTH AMERICA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY SMALL MOLECULES, 2025-2032 (USD MILLION)
  • TABLE 295. NORTH AMERICA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY HISTONE DEACETYLASE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 296. NORTH AMERICA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY HISTONE DEACETYLASE INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 297. NORTH AMERICA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PATIENT AGE, 2018-2024 (USD MILLION)
  • TABLE 298. NORTH AMERICA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PATIENT AGE, 2025-2032 (USD MILLION)
  • TABLE 299. LATIN AMERICA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 300. LAT